NCT04896112View on ClinicalTrials.gov

A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 8, 2021

Primary Completion Date

October 20, 2022

Study Completion Date

October 20, 2022

Conditions
Acute Myeloid LeukemiaPrimary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia MyelofibrosisPolycythemia Vera
Interventions
DRUG

LNK01002

LNK01002 will be administrated orally.

Trial Locations (2)

48314

Revive Research Institute, Sterling Heights

48334

Revive Research Institute, Farmington Hills

Sponsors
All Listed Sponsors
lead

Lynk Pharmaceuticals Co., Ltd

INDUSTRY

NCT04896112 - A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter